Abstract
Induction of apoptosis in cancer cells with chemotherapy and radiation treatment is a major strategy in cancer therapy at present. Nevertheless, innate or acquired resistance has been an obstacle for conventional clinical therapy. TNF-related apoptosis inducing ligand (TRAIL / Apo-2L) is a typical member of the TNF ligand family that induces apoptosis through activating the death receptors. In recent years, considerable attention has been focused on the potential benefits of TRAIL in cancer therapy, as the majority of cancer cells are sensitive to TRAIL-induced apoptosis, while most normal cells are TRAIL-resistant. Furthermore, the use of TRAIL in combination with chemotherapeutic agents or irradiation strengthens its apoptotic effects. In this review, we will discuss the regulation mechanism of TRAIL-induced apoptosis and the molecular basis of the synergies created by its use in combination with chemotherapeutic agents and irradiation. We also analyze in detail that TRAIL may be cytotoxic, as this is a potential obstacle to its development for being used in cancer therapy.
Keywords: trail, cancer therapy, tnf-related apoptosis inducing ligand, tnf ligand family, death receptors, trail-resistant
Current Molecular Medicine
Title: TRAIL: A Potential Agent for Cancer Therapy
Volume: 3 Issue: 8
Author(s): Juan Shi, Dexian Zheng, Kwan Man, Sheung-tat Fan and Ruian Xu
Affiliation:
Keywords: trail, cancer therapy, tnf-related apoptosis inducing ligand, tnf ligand family, death receptors, trail-resistant
Abstract: Induction of apoptosis in cancer cells with chemotherapy and radiation treatment is a major strategy in cancer therapy at present. Nevertheless, innate or acquired resistance has been an obstacle for conventional clinical therapy. TNF-related apoptosis inducing ligand (TRAIL / Apo-2L) is a typical member of the TNF ligand family that induces apoptosis through activating the death receptors. In recent years, considerable attention has been focused on the potential benefits of TRAIL in cancer therapy, as the majority of cancer cells are sensitive to TRAIL-induced apoptosis, while most normal cells are TRAIL-resistant. Furthermore, the use of TRAIL in combination with chemotherapeutic agents or irradiation strengthens its apoptotic effects. In this review, we will discuss the regulation mechanism of TRAIL-induced apoptosis and the molecular basis of the synergies created by its use in combination with chemotherapeutic agents and irradiation. We also analyze in detail that TRAIL may be cytotoxic, as this is a potential obstacle to its development for being used in cancer therapy.
Export Options
About this article
Cite this article as:
Shi Juan, Zheng Dexian, Man Kwan, Fan Sheung-tat and Xu Ruian, TRAIL: A Potential Agent for Cancer Therapy, Current Molecular Medicine 2003; 3 (8) . https://dx.doi.org/10.2174/1566524033479401
DOI https://dx.doi.org/10.2174/1566524033479401 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene Therapy for Prostate Cancer: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Poly (Lactic-co-Glycolic Acid) & Tocopheryl Polyethylene Glycol Succinate Nanoparticles for the Treatment of Different Brain Cancers
Anti-Cancer Agents in Medicinal Chemistry Practical Aspects in the Use of Biomarkers for the Development of Cancer Vaccines
Current Cancer Therapy Reviews The Application of Natural Products in Cancer Therapy by Targeting Apoptosis Pathways
Current Drug Metabolism The Polyamine Pathway as a Potential Target for Vascular Diseases: Focus on Restenosis
Current Vascular Pharmacology A Novel Polyarginine Containing Smac Peptide Conjugate that Mediates Cell Death in Tumor and Healthy Cells
Medicinal Chemistry Chemoprevention of Lung Pathologies by Dietary n-3 Polyunsaturated Fatty Acids
Current Medicinal Chemistry Gut Homing Molecule Regulation of the Pathogenesis and Treatment of Inflammatory Bowel Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Technologies for Translational Imaging Using Generators in Oncology
Recent Patents on Anti-Cancer Drug Discovery Identification of Drug Candidates for Breast Cancer Therapy Through Scaffold Repurposing: A Brief Review
Current Drug Research Reviews Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
Anti-Cancer Agents in Medicinal Chemistry The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer
Current Pharmaceutical Design Editorial [Hot Topic: Adrenergic Receptors as Novel Targets for Cancer Therapy (Guest Editors: D.G. Powe and F. Entschladen)]
Current Cancer Therapy Reviews Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging Latest Results for Anti-Angiogenic Drugs in Cancer Treatment
Current Pharmaceutical Design A Review of the Most Important Classes of Serine Protease Inhibitors in Insects and Leeches
Medicinal Chemistry Reviews - Online (Discontinued) Recognition of Invasive Prostate Cancer Using a GHRL Polypeptide Probe Targeting GHSR in a Mouse Model <I>In Vivo</I>
Current Pharmaceutical Design Current Advances in Therapy for Metastatic Melanoma
Current Cancer Therapy Reviews Anticancer Natural Coumarins as Lead Compounds for the Discovery of New Drugs
Current Topics in Medicinal Chemistry